drug · small molecule
rezafungin acetate
Marketedupdated 3mo agoby Napp Pharmaceuticals Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 2 investigational indications.
all catalysts(2)
Trials studying rezafungin acetate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 22, 2028
~1.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Jul 14, 2038compositionUS 11197909
- Jul 11, 2038compositionUS 11819533
- Mar 15, 2037formulationUS 11712459
- Mar 14, 2033compositionUS 10702573
- Mar 14, 2033compositionUS 9526835
- Mar 2, 2032compositionUS 11654196
- Mar 2, 2032compositionUS 8722619
FDA exclusivities (4)
- Mar 22, 2035GAINGAIN Antibiotic (5y)
- Mar 22, 2033GAINGAIN Antibiotic (5y)
- Mar 22, 2030ODE-426Orphan Drug (7y)3.6y
- Mar 22, 2028NCENew Chemical Entity (5y)1.6y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that